3 February 2021

Advanced Technology International (ATI)
ATTN: [b] (6), Contracts Administrator
315 Sigma Drive
Summerville, SC 29486

Dear [b] (6)

SUBJECT: Revised Project Approval Letter (PAL) for 20-09-COVID19-078 for “(b) (4) in the Treatment of Ambulatory Patients with Early Onset COVID-19”
Version 3

REF: Request for Project Approval from ATI dated 10 June 2020 for 20-09-COVID19-078 under OTA W81XWH-15-9-0001

EGS#: MT20009.78

This revised Project Approval Letter revises the data rights assertion table. For additional detail, see below.

In support of the U.S. Army Medical Research and Development Command (USAMRDC), ATI, on behalf of the Medical Technology Enterprise Consortium (MTEC) issued RPP 20-09-COVID19 on 25 March 2020. Members of the MTEC submitted Enhanced White Papers in response to this RPP, in accordance with the terms of the RPP and the Proposal Preparation Guide (PPG). [b] (4) Subsequently, the Government evaluated technical proposals in accordance with the stated evaluation criteria; [b] (4). Based upon the evaluation of Altimmune, Inc.’s proposal (20-09-COVID19-078) entitled, “(b) (4) in the Treatment of Ambulatory Patients with Early Onset COVID-19,” and ATI’s request for PAL (which includes the Statement of Work (SOW), inclusive of an acceptable milestone schedule), ATI is hereby authorized to issue a Research Project Award (RPA) to Altimmune, Inc. for the subject initiative. This approval is contingent upon the provision of funding via a separate Other Transaction Agreement Task Order, W81XWH-20-9-0005. At no time shall the Government’s obligation exceed the funding provided for this RPA. The Sponsor Office Technical Representative (SOTR) for this RPA is [b] (4), [b] (6).

The period of performance of the Research Project Award is 6 months. Note, however, that the period of performance within the Other Transaction Agreement Task Order, W81XWH-20-9-0008, includes additional time to account for the final negotiations between ATI and Altimmune,

Inc. to finalize negotiations for the RPA. This additional time is intended to align the end dates for the Task Order and RPA.

**SPECIAL CONSIDERATIONS**

External reviews and special considerations apply to this Research Project Award including use of human subjects. USAMRDC’s Office of Research Protections, Human Research Protections Office (HRPO) approval must obtained prior to commencement of any work involving use of human subjects.

**DATA RIGHTS**

<table>
<thead>
<tr>
<th>Technical Data or Computer Software to be Furnished with Restrictions</th>
<th>Basis for Assertion</th>
<th>Asserted Rights Category</th>
<th>Organization Asserting Restrictions</th>
<th>Milestone/Deliverable Affected</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>(b)(4)</em></td>
<td><em>(b)(4)</em></td>
<td>Government Purpose</td>
<td>Altimmune</td>
<td><em>(b)(4)</em></td>
</tr>
</tbody>
</table>

**PRE-AWARD COST AUTHORIZATION**

The Government has authorized pre-award costs for Research Project Award for Altimmune, Inc.’s proposal 20-09-COVID-19-078 starting 2 June 2020 in an amount not to exceed $87,175.00. The Government agrees to pay allowable costs accrued in the performance of this Research Project Award starting 2 June 2020 through the end of the period of performance.

The total authorized value has been determined fair and reasonable and this proposal has been selected IAW the RPP evaluation criteria. The Agreements Officer documented the appropriate use of Section 815 prototype OTA authority. The total approved cost to the Government for this effort is Not-to-Exceed (NTE) $4,725,000.00 as follows:
SUBJECT: PAL for 20-09-COVID19-078 for (b) (4) in the Treatment of Ambulatory Patients with Early Onset COVID-19, "Version 3"

<table>
<thead>
<tr>
<th>Government Project Funding</th>
<th>ATI Fixed Fee (Gov't Funding)</th>
<th>Total Cost to the Government</th>
<th>Anticipated Non-Federal Contribution</th>
<th>Total Project Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4,725,000.00</td>
<td>$0.00</td>
<td>$4,725,000.00</td>
<td>$0.00</td>
<td>$4,725,000.00</td>
</tr>
</tbody>
</table>

Sincerely,

BARTLETT.CH
ARLES.J.1042
185180
Charles J. Bartlett
Agreements Officer

Digitally signed by BARTLETT.CHARLES.J.1042
ESJ.1042185180

Enclosed:
Revised Statement of Work with Milestones